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Shakespeare1 and popular belief have
tended to reinforce the view that females
are weak. Scientific methodology applied
to the field of cardiovascular disease sug-
gests, to the contrary, that women are
strong and enduring2-7. Compared to males,
females live at least 4 years longer2,3, de-
velop ischemic heart disease about 10 years
later4, require more risk factors before
manifesting heart disease5, are less subject
to sudden cardiac death6, and appear to
have a more favorable outcome after the
onset of heart failure7.
What gives women their strength? A
first obvious candidate is the distinctive
hormonal milieu of females. However, re-
cent randomized studies of estro-progestins
have not confirmed the presumed cardio-
protective effect of these compounds when
given to postmenopausal women8,9. This
suggests either a flaw in the mode, type and
timing of hormonal replacement therapy, or
that other yet poorly-explored areas of fe-
male physiology may confer strength
against disease.
On the other hand, observational reg-
istry data suggest that women hospitalized
for ST-elevation acute myocardial infarc-
tion fare worse than their male counterparts,
even after adjusting for age, comorbidities,
extent of epicardial coronary artery disease,
left ventricular function at baseline, and
treatment strategies10. Thus, although
women relative to men enjoy a delay in the
onset of ischemic heart disease and its com-
plications, paradoxically more females than
matched males with ST-elevation acute my-
ocardial infarction appear to die in hospital.
Whether this observation reflects true dif-
ferences in biological processes or unidenti-
fied residual confounding factors still re-
mains to be established.
To advance our understanding of gen-
der-based differences in the manifestations
of cardiovascular disease, this issue of the
Journal inaugurates the first of two mini-
symposia dedicated to a sex-based com-
parison of the mechanisms, clinical pre-
sentation, and outcome of cardiovascular
disease. The project was conceived by the
Italian Society of Cardiology Working
Group on Cardiovascular Diseases in
Women. Its scope is to tackle some of sev-
eral unsettled questions, namely: 1) do car-
diovascular risk factors exert the same ef-
fect in male and female subjects; 2) can
different neurohumoral mechanisms ex-
plain the lower incidence of sudden car-
diac death among women; 3) what practi-
cal measures should cardiologists take to
face the sex-based differences in clinical
presentation, yield of invasive and non-in-
vasive diagnostic tests, and natural history
of disease; 4) last, but not least, do the
available data allow definitive conclusions
to be drawn on these matters, given that fe-
males have been largely under-represented
in cardiovascular clinical trials.
We hope this is only the beginning of a
far-reaching endeavor to better understand
female cardiovascular pathophysiology, in
order to recognize its distinctive features,
take advantage of its strengths, and inter-
vene more appropriately in the face of its
possible frailties.
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